A Patient’s Experience with Pseudo-Richter
August 11, 2026
When a BTKi is abruptly stopped a surgery, a few patients may have symptoms and pathology that looks like Richter, but is not and responds to restarting the BTKI.
When a BTKi is abruptly stopped a surgery, a few patients may have symptoms and pathology that looks like Richter, but is not and responds to restarting the BTKI.
A large prospective collaborative trial tests whether adding pirtobrutinib to standard R-CHOP improves outcomes in Richter transformation.
In an early-stage clinical trial, half of patients with relapsed / refractory Richter transformation responded to treatment with BTK degrader BGB-16673.
Though it is still early, the combination of pirtobrutinib-venetoclax-obinutuzumab appears to have good efficacy in patients with Richter transformation.
Half of patients with Richter transformation responded to treatment with epcoritamab, and outcomes were even better when it was used as a first-line therapy.
Half of patients with Richter transformation responded to treatment with epcoritamab, and outcomes were even better when it was used as a first-line therapy.
Outcomes for patients with Richter transformation remain poor even with the introduction of targeted therapies.
Profiling the metabolites produced by cells in Richter transformation could help researchers develop new ways to target therapies in the future.
CAR-T therapy can be effective in certain patients with Richter transformation.